【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2013 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2013 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2013 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2013 18
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2013 19
2.4.1 Shoppers Drug Mart Receives Ontario Court Approval for Its Acquisition by Loblaw for US$11.93 Billion 19
2.4.2 Amgen Completes Tender Offer to Acquire Onyx Pharma for up To US$10.4 Billion 21
2.4.3 Community Health Systems to Acquire Health Management Associates for up to US$7.6 Billion 22
2.4.4 Fresenius to Acquire 43 Hospitals from Rhon-Klinikum for US$4.1 Billion 23
2.4.5 Tenet Healthcare Prices Private Placement of Notes Due 2022 for US$2.8 Billion 24
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 25
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2013 25
3.1.1 Top M&A Deals in Q3 2013 26
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2012 – Q3 2013 27
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2013 29
3.2.1 Top Initial Public Offerings in Q3 2013 31
3.2.2 Top Secondary Offerings in Q3 2013 31
3.2.3 Top PIPE Deals in Q3 2013 31
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2012-Q3 2013 32
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2012 – Q3 2013 33
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2013 35
3.3.1 Top Venture Financing Deals in Q3 2013 36
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 37
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 38
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2012 – Q3 2013 39
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 41
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2012 – Q3 2013 43
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2013 44
3.4.1 Top Private Equity Deals in Q3 2013 45
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2012 – Q3 2013 46
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2013 48
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2013 48
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2012 – Q3 2013 50
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2013 52
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2013 54
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2013 54
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2013 55
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 – Q3 2013 56
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2012 – Q3 2013 58
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2012 – Q3 2013 59
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 – Q3 2013 61
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2013 63
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2013 63
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 – Q3 2013 65
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2013 67
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2013 67
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2013 68
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2012 – Q3 2013 69
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 – Q3 2013 71
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 – Q3 2013 73
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 – Q3 2013 74
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 – Q3 2013 76
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 78
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2012 – Q3 2013 78
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2012 – Q3 2013 80
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 – Q3 2013 82
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2012 – Q3 2013 84
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2012 – Q3 2013 86
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q3 2012 – Q3 2013 88
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 – Q3 2013 90
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 92
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2013 92
7.1.1 Oncology – Deals of the Quarter 94
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2013 96
7.2.1 Central Nervous System – Deals of the Quarter 98
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2013 101
7.3.1 Infectious Disease – Deals of the Quarter 103
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2013 105
7.4.1 Immunology – Deals of the Quarter 107
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2013 108
7.5.1 Metabolic Disorders – Deals of the Quarter 110
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2013 112
7.6.1 Cardiovascular – Deals of the Quarter 114
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2013 116
7.7.1 Gastrointestinal – Deals of the Quarter 118
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2013 119
7.8.1 Dermatology – Deals of the Quarter 121
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2013 122
7.9.1 Respiratory – Deals of the Quarter 124
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q3 2013 126
7.10.1 Ophthalmology – Deals of the Quarter 128
8 Deal Summary by Geography 130
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2013 130
8.1.1 North America – Deals of the Quarter 132
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2013 135
8.2.1 Europe – Deals of the Quarter 137
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2013 139
8.3.1 Asia-Pacific – Deals of the Quarter 141
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2013 144
8.4.1 Rest of the World – Deals of the Quarter 146
9 Pharmaceuticals & Healthcare, Global, Top Advisors 148
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 148
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 150
10 Appendix 152
11 Further Information 156
11.1 Methodology 156
11.2 About GlobalData 157
11.3 Disclosure information 158
11.4 Disclaimer 158
【レポート販売概要】
■ タイトル：事業提携・ライセンシング・投資・M&A動向（四半期別）：Q3 2013■ 英文：Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2013
■ 発行日：2013年11月30日
■ 調査会社：GlobalData
■ 商品コード：GDATA403162973
■ 調査対象地域：グローバル
- 世界ヘルスケア産業のLBS市場：Global LBS Market in the Healthcare Industry 2014-2018TechNavio's analysts forecast the Global LBS market in the Healthcare industry to grow at a CAGR of 29.36 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing requirement of real-time location-based people tracking in hospitals. The Global LBS market in the Healthcare industry has also been witnessing the increasing use of LBS in hospital g …
- DNO International ASA：石油・ガスバリューチェーン分析レポート2013DNO International ASA Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "DNO International ASA" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “DNO International ASA”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report e …
- Ovarian Cancer：グローバル臨床試験レビューH2, 2013Ovarian Cancer Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Ovarian Cancer Global Clinical Trials Review, H2, 2013" provides data on the Ovarian Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per …
- Dejour Energy Inc.：石油・ガスの開発・生産動向及びコスト分析- 2012Dejour Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - 2012 Summary Dejour Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key o …
- 産業用自動データ取込/認識装置の世界市場About automatic data capturing and identification systems Data capture is the mechanism of identifying and extracting data from scanned products for further processing. Automatic data capture refers to collecting data using automated data capture equipment, such as barcode readers/scanners, magnetic stripe readers, and cameras, or by using RFID technology. It requires no manual typing or punching …
- 自動車用ショックアブソーバーゴムの世界市場ABSTRACTAbout Automotive Shock Absorber Rubber Automotive shock absorber rubber is the rubber that is used for mounting and boot of shock absorbers to protect them from mud, water, pollutants, dust particles, and chipping stones. The raw rubber, which comprises of natural polymer or elastomer, can be divided into two broad categories, namely natural rubber and synthetic rubber. Technavio’s analyst …
- 医療用マットレスの世界市場2019-2023About this market The increasing number healthcare facilities coupled with surging rise in patient care services is one of the key driving factor for the market growth during our forecast period. The increasing demand for services such as post-treatment patient care services and home care services owing to the increasing healthcare instances. Additionally, issues like obesity lead to bariatric sur …
- フェムトセルの世界市場2015-2019About femtocell A femtocell is a small and lightweight cellular base station designed to increase the signal strength and coverage area of mobile networks, indoors and outdoors. It offers prompt data connections, in-building voice and data services, fewer dropped calls, and improved mobile voice quality to enterprises and residential consumers. The femtocell technology can be easily deployed becau …
- 中国のEV充電スタンド市場2016-2020About the Electric Vehicle Charging Station Market in China China has been aggressive in its efforts to promote EV adoption, primarily to cope with the growing pollution scenario. China was placed at the top of the nations with the most carbon dioxide emissions in 2011. China’s tremendous economic growth has been riding on the country’s manufacturing sector, which has been a key contributor to the …
- グローバル水力発電市場（2014-2018）About Hydropower Hydropower is the most mature, reliable and cost-effective renewable power generation technology where power is derived from the energy of water moving from higher to lower elevations. It is a proven, anticipated, and typically price-competitive technology. Hydropower has one of the best efficiencies of conversion of all known energy sources (water to wire 90 percent efficiency). …
- ベントナイトの世界市場2017-2021About Bentonite Bentonite is a sedimentary deposit; it is volcanic in origin and contains more than 50% montmorillonite. Bentonite is surface mined, dried, crushed, and sent through grinding mills to be sized based on customer requirements. Processed bentonite can also be chemically modified. Bentonite has a unique chemical structure that enables it to act as a sealant, binder, thickener, lubrican …
- 医療廃棄物管理の世界市場The medical waste management market is expected to reach USD 13.3 billion by 2020 from USD 10.3 billion in 2015, at a CAGR of 5.2%. The global medical waste management market is segmented based on type of waste, services, treatment type, treatment site, and geography. The treatment and disposal segment is expected to register the highest growth rate in the medical waste management market, by servi …
- 公衆安全及びセキュリティの世界市場MarketsandMarkets forecast the public safety and security market size to grow from USD 220.82 Billion in 2015 to USD 370.64 Billion by 2020, at a Compound Annual Growth Rate (CAGR) of 10.91% from 2015 to 2020. The public safety and security solutions help avert and minimize the impact of terrorist attacks, cyberattacks, and natural disasters on economy. It is the primary responsibility of the publ …
- Penn West Exploration：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Penn West Exploration Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Penn West Exploration Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source …
- Head And Neck Cancer：グローバル臨床試験レビューH2, 2013Head And Neck Cancer Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Head And Neck Cancer Global Clinical Trials Review, H2, 2013" provides data on the Head And Neck Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Head And Neck Cancer. It includes an overview of the trial numbers and their r …
